Tirzepatide, sold as the FDA-approved brand Zepbound™ for chronic weight management and as Mounjaro® for type 2 diabetes, is also available as a compounded medication through licensed pharmacies. Whichever form you are prescribed, you will probably notice that your dose does not start at its final, ongoing level. Tirzepatide dosing is designed to start low and increase gradually over several weeks, a process clinicians call titration. Here is why the schedule works that way, what the Zepbound™ label spells out step by step, and what to expect as your dose changes.
This article is patient education, not medical advice. It does not create a doctor-patient relationship and is not a substitute for an individualized evaluation from a licensed clinician who knows your health history.
Why tirzepatide dosing starts low and rises gradually
Tirzepatide works by activating GLP-1 and GIP receptors, hormone pathways involved in appetite and blood sugar regulation. Introducing a full dose right away tends to produce more pronounced gastrointestinal side effects, so the FDA-approved prescribing information for Zepbound™ starts everyone at a low dose and increases it in planned steps. This gives the digestive system time to adjust at each level before the next increase, which is intended to make the side-effect profile more manageable as the dose rises toward an effective maintenance level.
This step-up approach, often called titration, is standard across GLP-1 and dual GLP-1/GIP medications; it is not unique to tirzepatide. If you have compared it with a related molecule before, our overview of semaglutide vs. tirzepatide covers how their dosing and step-up schedules differ in more detail.
The labeled step-up schedule for Zepbound™
The FDA-approved prescribing information for Zepbound™ lays out a specific step-up schedule. Treatment starts with a 2.5 mg dose injected once weekly for 4 weeks. This starting dose is intended for treatment initiation only, not as an ongoing maintenance dose. After the first 4 weeks, the label calls for increasing the dose in 2.5 mg increments, with at least 4 weeks spent on each dose before moving to the next step, continuing upward through intermediate levels toward one of three labeled maintenance doses.
| Step | Minimum time at this step | Dose | Purpose |
|---|---|---|---|
| Starting dose | 4 weeks | 2.5 mg once weekly | Treatment initiation only, not a maintenance dose |
| First increase | 4 weeks | 5 mg once weekly | First labeled maintenance dose option |
| Further increases | 4 weeks per step | Rises in 2.5 mg increments | Only if more effect is needed and the current dose is well tolerated |
| Higher maintenance | Ongoing | 10 mg or 15 mg once weekly | 15 mg once weekly is the labeled maximum |
If you are weighing the FDA-approved product against a compounded option, our guide to compounded tirzepatide vs. Zepbound™ walks through what is the same and what differs between the two before you start any titration plan.
Starting dose versus maintenance dose
It helps to understand that the 2.5 mg starting dose is not meant to be an effective, ongoing treatment dose. The Zepbound™ label is explicit that 2.5 mg is for treatment initiation only, used for the first 4 weeks to let the body adjust before any dose that is expected to produce an ongoing effect.
The maintenance dose, the one a person stays on for ongoing treatment, is 5 mg, 10 mg, or 15 mg once weekly. Which maintenance dose someone lands on is not predetermined; the prescribing clinician selects it based on how well the medication is working and how well it is tolerated, and a lower maintenance dose can be a reasonable, deliberate choice if a higher one causes side effects that outweigh its benefit.
Want to know if tirzepatide could work for you?
What to expect when a dose changes
Many people notice gastrointestinal symptoms, such as nausea, diarrhea, or a reduced appetite, are more noticeable in the days after a dose increase, then ease as the body adjusts to the new level over the following days or weeks. This pattern, side effects tracking dose changes more closely than the passage of time at a stable dose, is part of why the schedule moves slowly rather than reaching an effective dose immediately. Some people also notice the plateau in appetite or weight change described in our guide to the GLP-1 weight-loss plateau, which can prompt a conversation about whether a dose adjustment makes sense.
Keep taking the medication on the same day each week unless your clinician tells you otherwise, and do not increase your own dose ahead of schedule even if side effects feel manageable, since a faster increase is associated with a higher chance of gastrointestinal side effects. If you miss a dose or are unsure how a missed dose affects your schedule, ask your clinician rather than guessing; the right next step depends on how much time has passed since your last dose.
Why dosing is individualized by a clinician
The step-up schedule gives a framework, but the pace and final maintenance dose are not one-size-fits-all. A prescribing clinician decides when to move to the next dose based on how you are tolerating the current one and what you and your clinician are trying to achieve, and the label itself allows for staying at a lower dose, or returning to one, if side effects warrant it.
This is also why the schedule described in this article is a general, labeled framework, not a prediction of exactly how your own treatment will unfold. An independent licensed clinician reviewing your specific history, other medications, and response is in the best position to decide how your dose should change over time.
Compounded tirzepatide: how its dosing schedule can differ
Not everyone is prescribed the FDA-approved Zepbound™ or Mounjaro® brand products. Tirzepatide is also available as a compounded medication, often prescribed when a patient has a specific clinical need that is not met by the commercially available product. Compounded medications are not FDA-approved but may be prescribed by independent licensed physicians when clinically appropriate. Our explainer on how compounded GLP-1s work covers what "compounded" means in more detail, and what is compounded tirzepatide looks specifically at this molecule.
Because compounded tirzepatide is not the FDA-approved product, its dosing schedule is set by the prescribing clinician and the compounding pharmacy's formulation, and it is not required to match the labeled Zepbound™ step-up schedule described above. FDA-approved brand products, Wegovy®, Ozempic®, Mounjaro®, and Zepbound™, have each been evaluated by the FDA for safety, effectiveness, and quality at their labeled doses; compounded versions have not gone through that same FDA evaluation. If you are prescribed compounded tirzepatide, ask your clinician to walk through your specific titration plan rather than assuming it mirrors the Zepbound™ schedule.
When to call your clinician
Contact your clinician promptly if you develop severe abdominal pain that may radiate to your back, with or without vomiting, which can be a sign of pancreatitis; signs of a gallbladder problem, such as pain in the upper right abdomen, fever, or yellowing of the skin or eyes; symptoms of a serious allergic reaction, such as swelling of the face or throat or difficulty breathing; or any side effect that feels severe or is not improving as expected after a dose change.
Also mention persistent nausea, vomiting, or diarrhea that is affecting your ability to eat, drink, or take other medications, since these can sometimes be managed with a slower titration pace or supportive measures rather than stopping treatment altogether. Do not change your own dose, skip scheduled increases, or add extra doses without talking to your clinician first.
The bottom line
Tirzepatide dosing is designed to start low and rise gradually, whether you are prescribed the FDA-approved Zepbound™ or Mounjaro® or a compounded version. The labeled schedule for Zepbound™ begins at 2.5 mg for 4 weeks, intended only to start treatment, then increases in 2.5 mg steps with at least 4 weeks at each level toward a maintenance dose of 5 mg, 10 mg, or 15 mg weekly. Your prescribing clinician sets the actual pace and final dose for your situation based on how you respond and tolerate each step. You can find more articles like this one in our Weight Management section.
Important Safety Information
Indication. Zepbound™ (tirzepatide) is FDA-approved for chronic weight management in adults with obesity, or with overweight and at least one weight-related medical condition, used along with a reduced-calorie diet and increased physical activity. Tirzepatide is also FDA-approved as Mounjaro® for type 2 diabetes. Compounded tirzepatide is not FDA-approved.
Common side effects. The most commonly reported side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, injection-site reactions, and fatigue; these are often more noticeable in the days after a dose increase.
Warnings. Zepbound™ carries a boxed warning regarding thyroid C-cell tumors seen in rodent studies and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Other warnings include the risk of pancreatitis, gallbladder problems, severe gastrointestinal disease, acute kidney injury related to dehydration from gastrointestinal side effects, hypoglycemia when used with insulin or sulfonylureas, and serious hypersensitivity reactions.
Talk to your doctor. This information is educational and is not a substitute for medical advice. Only a licensed medical professional can determine whether a treatment is right for you. Talk to your doctor about the benefits and risks, and report any side effects.
Frequently asked questions
What is the starting dose of tirzepatide?
For the FDA-approved Zepbound™ brand, the labeled starting dose is 2.5 mg injected once weekly for the first 4 weeks. This starting dose is intended for treatment initiation only and is not meant to be an ongoing maintenance dose.
How often does the tirzepatide dose increase?
According to Zepbound™ prescribing information, the dose rises in 2.5 mg steps, with at least 4 weeks spent on each dose before moving to the next one. This gradual pace is designed to let the body adjust and to make gastrointestinal side effects more manageable.
What is the highest tirzepatide dose?
The labeled maximum maintenance dose of Zepbound™ is 15 mg once weekly. Not everyone needs to reach this dose; a clinician selects a maintenance dose of 5 mg, 10 mg, or 15 mg based on response and tolerability.
Is compounded tirzepatide dosed the same way as Zepbound™?
Not necessarily. Compounded tirzepatide is not FDA-approved, and its dosing schedule is set by the prescribing clinician rather than the Zepbound™ label. If you are prescribed a compounded version, ask your clinician to explain your specific titration plan.
What happens if side effects get worse after a dose increase?
Gastrointestinal side effects such as nausea or diarrhea are often more noticeable in the days right after a dose increase and may ease as the body adjusts. If side effects are severe or are not improving, contact your clinician, who may suggest staying at the current dose longer rather than stopping treatment altogether.
Can I stay on a lower maintenance dose if it is working for me?
Yes. The Zepbound™ label allows for 5 mg, 10 mg, or 15 mg as maintenance doses, and a clinician can choose to keep you at a lower dose if it is meeting your treatment goals and is well tolerated, rather than automatically increasing to the maximum.
